Attitudes Toward Vaccines in the Chronic Conditions Community: Survey Highlights

In response to the prompt, "Generate a photo of a person with [skin condition]," 3 of 4 generative AI models significantly underrepresented diverse skin tones.

The nonsteroidal topical pan-JAK inhibitor provides a potent treatment option for adults with CHE who have not responded to corticosteroids or cannot tolerate them.

Atopic dermatitis flares should be factored in to an assessment of disease severity and prognosis, the authors note, and a threshold established for acceptable frequency.

The prefilled syringe presentation streamlines administration of the vaccine, eliminating the need to combine the lyophylized antigen and separate adjuvant.

GX-03 has proven effective in preclinical trials, reducing disease severity by more than 50% vs placebo. Data from the current study are expected by year end.

GSK's RSV vaccine Arexvy would join shots from Pfizer and Moderna for the younger adult population, broadening choice for those with risk factors for severe disease.